




Livio Valenti

Livio Valenti is an entrepreneur working alongside top scientists leveraging scientific discoveries to build new ventures. He is the co-founder of Vaxess Technologies, an MIT and Tufts University biotechnology spin-off developing a new class of vaccines (that do not require refrigeration and can be self-administered painlessly directly in the skin). He was also co-founder of Mori, an MIT advanced materials company using engineered silk fibroin to eliminate food waste and Moveo, a commercial stage advanced engineering company selling the world's lighter, passive exoskeleton, originally conceived at Harvard University.

Those companies raised more than \$155mn in Venture Capital and Government funding to date, pioneering a sustainable model of venture creation in collaboration between top-tier R&D centers, investors and corporate partners.

Livio is also research fellow at the Belfer Center for Science and International Affairs at Harvard University, where he focuses on mapping and assessing critical technologies developed at US Government Labs. Livio is a Forbes 30 under 30 honoree (US), Wire Magazine Top Innovator under 35, a fellow at the Atlantic Council, a TEDx speaker and an affiliate with the Aspen Institute. Livio was previously an economist at the United Nations. He graduated with honors from the Harvard Kennedy School of Government (2013), Bocconi University (Italy) and Fudan University (China).



Matteo Biagini

Born in a little town in Bologna in 2003, Matteo has been living and studying there all his life.

He grew fond of chemistry and of the philosophy of science in general. Throughout the formation years he improved his photography techniques and learnt how to produce and edit different kind of media content while striving to make his hobby a remunerative way to spend his time.

He is currently enrolled in a degree programme in pharmaceutical chemistry and technologies at the university of Bologna.



Evelyne Yehudit Bischof

Specialist in Internal Medicine, Artificial Intelligence (AI) and digital health, with extensive experience in scientific research and clinical practice at the following well known and highly reputable institutions. Research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. EB published over 100 peer-reviewed papers, is a frequent speaker at scientific and medical conferences in Asia and Europe. Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc.

Evelyne spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: University Hospital of Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital and Shanghai East Hospital. EB sits on several scientific and advisory boards of biotech and longevity hubs. Currently also affiliated with the Centre of Healthy Aging, Universität Zürich, and prev. senior attending physician of internal medicine at the University Hospital Basel.

Swiss board certified as internal medicine specialist (FMH), trained in Europe, USA and China (Harvard Medical School affiliated hospitals (Mass General Hospital, Beth Israel MD, Dana Farber Institute) and Columbia University NYC; Tongji University hospitals, Shanghai and University Hospitals of Zürich and Basel (Switzerland).



Giuliana Calabrese

Giuliana Calabrese is a 25-year-old biotechnologist with a passion for science and healthcare. She completed her Bachelor's degree in Biotechnology at the Vita-Salute San Raffaele University in Milan and later pursued her Master's degree at the Cattolica del Sacro Cuore University in Rome.


She received recognition for her research, including the Renato Dulbecco prize for a paper on molecular switches and microRNAs in 2016 and a scholarship from the "Reproduction and Fertility" society in 2019. Giuliana's research experience extends to cardiovascular diseases, gastroenterological diseases, and personalized medicine in oncology, collaborating with institutions such as the Mario Negri Institute, San Raffaele Hospital, and Gemelli Hospital.

After a working experience in 2022 on clinical trials at Gemelli Hospital, she has moved from the world of research to the world of the pharmaceutical industry.

Currently, Giuliana is pursuing a Graduate Program at Thermo Fisher Scientific, where she is specializing in technology transfer for injectable biotech drugs, from development to commercial production, rotating through different departments (such as Process Engineering, Process and Cleaning Validation, Operational Excellence...) in order to become Technology Transfer Project Manager.

In 2023, Giuliana became a member of Nucleate, a bioentrepreneur community, allowing her to connect with like-minded professionals in the biotech field. She also joined the Aeon Foundation, as Project Manager, actively engaging in projects that aim to translate the latest scientific research in the field of technologically driven longevity into policies capable of improving quality of life and longevity.





Alessandro Cascavilla

Alessandro Cascavilla is a Post-Doc researcher in Economic Policy at Università degli Studi di Roma Unitelma Sapienza and Adjunct Professor of Macroeconomics and Public Finance at the University of Bari "Aldo Moro".

He holds a PhD in Economics cum laude at the University of Bari in co-tutorship with Universitat Jaume I (Spain), a double Master's Degree cum laude in International Economics at UNIVPM and UJI, and a Bachelor's Degree in Economics and Commerce cum laude at UNIVPM.

He has been working as a Junior Economist at the Italian Public Accounts Monitor of the Catholic University (Rome).

He manages an audience of over 200.00 young people on social media (Instagram), where he carries out several economic and financial literacy projects. He collaborates with various institutions (Istat, Eurostat), Companies (Reale Mutua, Scalable Capital), Universities (Scuola Superiore Sant'Anna di Pisa, Luiss Business School) and media (Le fonti TV, Next Quotidiano).



Romina Cervigni

Dr Cervigni is a nutritional biologist. She completed her PhD at the Open University in the UK, focusing on studying the cellular and molecular mechanisms of tumor cells through research in basic biology.

Subsequently, she collaborated as a postdoctoral researcher with the National Research Committee (CNR) in Naples and the Vita-Salute San Raffaele University in Milan, with particular interest in neuroscience. His professional career continued at the Polytechnic University of Marche, where he undertook a second level Master's degree in Nutrition and Dietetics. This path has allowed her to combine her preparation and knowledge acquired over the years in various pathological areas with tools to maximize the therapeutic potential of nutrition. Together with the entire team of the Valter Longo Foundation, she assists patients from all over the world who are affected by various pathologies on a daily basis. Their goal is to help these patients integrate nutritional therapy with standard pharmacological treatments.



Federico Pio Fabrizio

Biotechnologist, he currently a postdoctoral fellow in Oncology research field with a PhD in Experimental and Regenerative Medicine. Federico is also a science communicator of "Pillole di Ricerca Scientifica", a project with a good impact on social media networks (~100k followers).





Monica Galiano

Monica Galiano is a professional, with over twenty years of experience in international relations.

During her professional career she has had the opportunity to collaborate with diplomatic missions accredited to the Vatican and to the Italian Republic. In this context, she has worked organizing and managing foreign delegations for high level bilateral meetings, events, and more.

During the last legislature she has worked as a parliamentary assistant organising the agenda, meetings, and events.

Multitasking, problem solving, flexibility are what people appreciate the most about her. She currently works at the Italian Ministry of Foreign affairs.



Chiara Herzog

Dr Chiara Herzog is a translational scientist at the University of Innsbruck and University College London, specialising in aging and cancer risk biomarkers.

She co-led one of the most detailed human prevention and longevity studies to date, generating over 1 billion longitudinal clinical and molecular datapoints from 156 participants. Herzog is actively promoting the standardisation of biomarkers of aging to advance them into promising clinical tools for personalised prevention, and has a keen interest in improving healthcare inclusivity.





Niccolò Invidia

Niccolò is a tech policy and innovation economics expert. He firstly worked as a researcher in several institutes, subsequently at the European Parliament and, more recently, as a Member of Parliament in Italy (2018-2022).

In this position, he held the roles of President of the Space Parliamentary group, Co-coordinator of the Parliamentary group for Innovation, and Party leader in the Labor Committee. During the parliamentary activities he has promoted proposals on numerous topics, including: smart work, A.I., flex work, innovation committee, digital economy Index (DESI), space governance, gig work, internships, big data for public administration, right to disconnect, digital signatures for referenda, technical colleges (ITS), longevity medicine, etc. With Nicola Marino, he works at Aeon to develop longevity and cognitive enhancement policies and researches.



Nicola Marino

With a medical-scientific background, he conducts scientific research with the Swiss group Women's Brain Project on emerging medical technologies, particularly artificial intelligence algorithms, and in the longevity and digital health field. With consolidated skills also thanks to the research carried out at Harvard Medical School and the Dana Farber Cancer Institute center in Boston in the laboratory directed by Charlotta Lindvall, MD, Ph.D.

Nicola is co-author of scientific publications on exponential technologies in medicine and data-driven precision medicine, including a (peer-reviewed) paper in the prestigious npj journal Digital Medicine - Nature.

Winner of the Human Machine Interactions Summer School (HMISS) and Heroes for research, thanks to a project on the use of augmented reality and IoT devices in cardiology, Nicola is also a speaker at international events, including two TEDx, Singularity University (Rome) and Florence Health Forum, for which he was the youngest member of the scientific committee for two consecutive years. In March 2019, he co-founded the innovative startup INTECH-Innovative Training Technologies, engaged in developing advanced surgical training systems. Training devices that, on the "phygital" model, mix physical models and digital and computational technologies scientifically validated by the most important international scientific societies to provide high training standards in a decentralized way.

Nicola worked as a consultant for the American company, the world leader in health data analysis, Health Catalyst, based in Salt Lake City (Utah, USA). He has also held the role of political consultant on digital health and longevity since 2019, carrying out activities at the Italian Chamber of Deputies.

He is a digital health advisor for the publicly traded innovative startup incubator, Digital Magics. Nicola is also involved in scientific journalism, with numerous articles published in international and national newspapers (for example, CFI.co, IlSole24Ore, Corriere Della Sera, Millionaire) as interventions on Rai1, and SkyTG24, to name a few.

In March 2020, Forbes Italia nominated Nicola among the "Top 100 under 30", thanks to the research efforts to move surgical training towards a new paradigm driven by emerging technologies, decentralized and democratic. Finally, he is a member of the Scientific Committee of AiSDeT-Italian Association of Digital Health and Telemedicine and Head of the Department of Digital Health of the association in defense of consumers Consumerism.



Antonluca Matarazzo

Lawyer and manager with many years of international experience in management and business development. Already Executive Director of the Create Cures Foundation in Los Angeles, since 2020 he has held the position of CEO and Vice President of the Valter Longo Foundation in Italy, a non-profit organization founded in 2017 by will of Professor Valter Longo with the objective of optimizing healthy longevity, which begins as early as children and continues throughout the entire life cycle, promoting a healthy lifestyle and eating habits that can slow down and counteract the onset of important pathologies related to advancing age or non-communicable diseases including tumors, diabetes, obesity, cardiovascular diseases, autoimmune diseases, such as Crohn's disease and multiple sclerosis, and neurodegenerative diseases such as Alzheimer's.

During his career, also through the creation of successful partnerships, he has implemented and directed numerous entrepreneurial projects in various areas including Africa, Europe and the Middle East, mainly on behalf of Italian companies. He contributed to and defined the strategic corporate processes of the same, as well as having directed specific departments and work teams. Before moving to the United States, he mainly worked on projects in the renewable energy, IT, real estate and civil or infrastructural works, as well as financial sectors, taking on positions of increasing responsibility over the years



Marco Quarta

Dr. Marco Quarta is co-founder and president of the Phaedon institute, a think-tank organization that operates with the mission of supporting and enabling effective and sustainable growth in the field of aging and longevity sciences a non profit scientific organisation with a focus on Longevity medicine and sciences. Quarta is also co-founder and CEO of Rubedo Life Sciences, a longevity biotech company, driving its mission to develop treatments for chronic age-related diseases and extend healthspan. Rubedo strategy is based on a platform to discovers the pathological cells involved in the biological aging process, such as senescent-like cells, and to develop small molecules designed for selectively targeting those cells across multiple indications in the Rubedo pipeline.

As a scientist, he earned a Masters degree in Biotechnology from the University of Bologna, a PhD in Neuroscience from the University of Padua, and post-doctoral training in Aging and Stem Cells Biology in the lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then directed at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine.

He is backed by over 20 years of research with a track record of scientific publications in top tier journals and international patents. He also co-founded the biotech company WetWare Concepts and the rejuvenation company Turn Biotechnologies, based on his work conducted at Stanford University with colleague Dr. Sebastiano on transient epigenetic reprogramming. He also sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) – Calpoly program in regenerative medicine. He is in the advisory and research board at the Center for Healthcare Innovation (CHI) and a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University.



Bryan Scarano

Born in Rome in 1997, Bryan has practiced various sports and hobbies, or more recently interacting and collaborating with engineers, doctors and researchers from different fields (collaborations that will also lead to the publication of a Review with the topic Longevity and Artificial Intelligence in the journal "Frontiers in Aging"); all these activities are carried out in parallel with his studies, which ended after a few years of laboratory experience (mainly in the field of Proteomics), with a Master's degree in Biotechnology for Personalised Medicine with honors.

He currently holds the position of Technology Transfer Project Manager for ThermoFisher at the Monza production site; although this is his first post-graduate job, this is not his first work experience: at this point in his career, Bryan already has several years of work experience in catering and tourism behind him; fields that are certainly different from the scientific/pharmaceutical field, but which have enabled him to develop interpersonal skills and attitude for management.



Andrew Steele

Andrew is a scientist, writer and campaigner based in Berlin, and author of *Ageless: The new science of getting older without getting old*. After a PhD in physics from the University of Oxford, he decided that ageing was the single most important scientific challenge of our time, and switched fields to computational biology. He worked at the Francis Crick Institute, using machine learning to decode our DNA and predict heart attacks using patients' NHS medical records.

Andrew is now a full-time science writer and presenter. He has written for the *Wall Street Journal*, *Sunday Times*, *Telegraph*, *Guardian* and *WIRED* magazine, and have featured on NBC's *TODAY*, *The Russell Howard Hour*, *Sunday Brunch*, *NBC Morning News Now* and *BBC News*, as well as being a regular expert on *Discovery's Impossible Engineering* and *Strangest Things on Sky*. He also produces videos on his YouTube channel, and give live talks ranging from lectures in schools to science stand-up (yes, that is a thing) at the *Hammersmith Apollo*. He has also campaigned about science funding as *Chair of Science is Vital* and creator of *Scienceogram*.



Aureliano Stingi

Born in 1991, with a degree in Molecular Biotechnology, he obtained a PhD in Cancer Biology at the University of Geneva. He is passionate about the world of start-ups and in 2022 he obtains an international MBA.

He currently works in a biomedical start-up, Medendi, which deals with precision oncology. At the same time he cultivates his passion for scientific dissemination: he edits a column in "Repubblica Salute" journal, collaborates with Will Media and is a member of the scientific committee of LILT Rome and of the Navacchio Technological Pole.



Alex Zhavoronkov

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation generative artificial intelligence technologies for drug discovery and biomarker development. Under his leadership, Insilico raised over \$400 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 11 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. Since 2015 he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. Since 2012 he published over 160 peer-reviewed research papers and 2 books. He founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.